Self-assembled cationic-covered nanoemulsion as a novel biocompatible immunoadjuvant for antiserum production against Tityus serrulatus scorpion venom

Full metadata record
DC FieldValueLanguage
dc.contributor(LBI) Lab. Imunoquímicapt_BR
dc.contributor.authorMedeiros, Arthur Sérgio Avelino dept_BR
dc.contributor.authorTorres-Rêgo, Manoelapt_BR
dc.contributor.authorLacerda, Ariane Ferreirapt_BR
dc.contributor.authorRocha, Hugo Alexandre Oliveirapt_BR
dc.contributor.authorEgito, Eryvaldo Sócrates Tabosa dopt_BR
dc.contributor.authorCornélio, Alianda Mairapt_BR
dc.contributor.authorTambourgi, Denise Vilarinhopt_BR
dc.contributor.authorFernandes-Pedrosa, Matheus de Freitaspt_BR
dc.contributor.authorSilva-Júnior, Arnóbio Antônio dapt_BR
dc.date.accessioned2020-10-08T13:57:35Z-
dc.date.available2020-10-08T13:57:35Z-
dc.date.issued2020pt_BR
dc.identifier.citationMedeiros ASA, Torres-Rêgo M, Lacerda AF, Rocha HAO, Egito EST, Cornélio AM, et al. Self-assembled cationic-covered nanoemulsion as a novel biocompatible immunoadjuvant for antiserum production against Tityus serrulatus scorpion venom. Pharmaceutics. 2020 Sept;12(10):927. doi:10.3390/pharmaceutics12100927.pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/3265-
dc.description.abstractThis study assesses the efficacy of different nanoemulsion formulations as new and innovative adjuvants for improving the in vivo immunization against the Tityus serrulatus scorpion venom. Nanoemulsions were designed testing key-variables such as surfactants, co-solvents, and the influence of the temperature, which would be able to induce the phase transition from a liquid crystal to a stable nanoemulsion, assessed for four months. Additionally, cationic-covered nanoemulsion with hyper-branched poly(ethyleneimine) was prepared and its performance was compared to the non-cationic ones. The physicochemical properties of the selected nanoemulsions and the interactions among their involved formulation compounds were carefully monitored. The cytotoxicity studies in murine macrophages (RAW 264.7) and red blood cells were used to compare different formulations. Moreover, the performance of the nanoemulsion systems as biocompatible adjuvants was evaluated using mice immunization protocol. The FTIR shifts and the zeta potential changes (from −18.3 ± 1.0 to + 8.4 ± 1.4) corroborated with the expected supramolecular anchoring of venom proteins on the surface of the nanoemulsion droplets. Cell culture assays demonstrated the non-toxicity of the formulations at concentrations less than 1.0 mg/mL, which were able to inhibit the hemolytic effect of the scorpion venom. The cationic-covered nanoemulsion has shown superior adjuvant activity, revealing the highest IgG titer in the immunized animals compared to both the non-cationic counterpart and the traditional aluminum adjuvant. In this approach, we demonstrate the incredible potential application of nanoemulsions as adjuvants, using a nanotechnology platform for antigen delivery system on immune cells. Additionally, the functionalization with hyper-branched poly(ethyleneimine) enhances this recognition and improves its action in immunizationpt_BR
dc.description.sponsorship(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológicopt_BR
dc.description.sponsorship(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superiorpt_BR
dc.format.extent927pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofPharmaceuticspt_BR
dc.rightsOpen accesspt_BR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/pt_BR
dc.titleSelf-assembled cationic-covered nanoemulsion as a novel biocompatible immunoadjuvant for antiserum production against Tityus serrulatus scorpion venompt_BR
dc.typeArticlept_BR
dc.rights.licenseCC BYpt_BR
dc.identifier.doi10.3390/pharmaceutics12100927pt_BR
dc.identifier.urlhttps://doi.org/10.3390/pharmaceutics12100927pt_BR
dc.contributor.external(UFRN) Universidade Federal do Rio Grande do Nortept_BR
dc.identifier.citationvolume12pt_BR
dc.identifier.citationissue10pt_BR
dc.subject.keywordTityus serrulatus antiserumpt_BR
dc.subject.keywordnanoemulsion adjuvantpt_BR
dc.subject.keywordliquid crystalpt_BR
dc.subject.keywordphase transitionpt_BR
dc.subject.keywordsurface functionalizationpt_BR
dc.subject.keywordimmunoadjuvantpt_BR
dc.relation.ispartofabbreviatedPharmaceuticspt_BR
dc.identifier.citationabntv. 12, n. 10, 927, set. 2020pt_BR
dc.identifier.citationvancouver2020 Sept;12(10):927pt_BR
dc.contributor.butantanTambourgi, Denise Vilarinho|:Pesquisador:Docente permanente PPGTOX|:Lab. Imunoquímicapt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦308382/2017-0pt_BR
dc.sponsorship.butantan(CNPq) Conselho Nacional de Desenvolvimento Científico e Tecnológico¦¦436051/2018-4pt_BR
dc.sponsorship.butantan(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior¦¦23038.007487/2011-91pt_BR
dc.sponsorship.butantan(CAPES) Coordenação de Aperfeiçoamento de Pessoal de Nível Superior¦¦001pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.grantfulltextopen-
item.openairetypeArticle-
item.fulltextCom Texto completo-
item.languageiso639-1English-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0003-1896-9074-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos


Files in This Item:

10.3390pharmaceutics12100927.pdf
Description:
Size: 2.5 MB
Format: Adobe PDF
View/Open
Show simple item record

This item is licensed under a Creative Commons License Creative Commons